Among other key products in the portfolio are cholesterol-lowering medicine Lipitor, anti-epileptic drug Lyrica, antidepressant Zoloft, hypertension medicine Norvasc and Celebrex, an anti-inflammatory medication. These are being acquired from Nasdaq-listed drug maker Viatris, with Aspen paying $150 million in cash for the portfolio and settling the balance through an extension of supply terms to Viatris.
"Due to the way the products have been integrated into Viatris' business, it is not possible to accurately determine or estimate the profit attributable to the products within Viatris," the group said.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Aspen seeks to lift Latin American business in R5bn deal with ViatrisThe drugmaker secured the commercialisation rights and related intellectual property for products such as Viagra and Lipitor
ソース: BDliveSA - 🏆 12. / 63 続きを読む »
ソース: BusinessTechSA - 🏆 24. / 61 続きを読む »